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Objectives The aim of this study was to describe the process to obtain Food and Drug Administration
(FDA) approval for the expanded indication for treatment with the Resolute zotarolimus-eluting stent
(R-ZES) (Medtronic, Inc., Santa Rosa, California) in patients with coronary artery disease and diabetes.
Background The R-ZES is the ﬁrst drug-eluting stent speciﬁcally indicated in the United States for
percutaneous coronary intervention in patients with diabetes.
Methods We pooled patient-level data for 5,130 patients from the RESOLUTE Global Clinical Program.
A performance goal prospectively determined in conjunction with the FDA was established as a rate of
target vessel failure at 12 months of 14.5%. In addition to the FDA pre-speciﬁed cohort of less complex
patients with diabetes (n  878), we evaluated outcomes of the R-ZES in all 1,535 patients with diabetes
compared with all 3,595 patients without diabetes at 2 years.
Results The 12-month rate of target vessel failure in the pre-speciﬁed diabetic cohort was 7.8% (upper
95% conﬁdence interval: 9.51%), signiﬁcantly lower than the performance goal of 14.5% (p  0.001).
After 2 years, the cumulative incidence of target lesion failure in patients with noninsulin-treated diabe-
tes was comparable to that of patients without diabetes (8.0% vs. 7.1%). The higher risk insulin-treated
population demonstrated a signiﬁcantly higher target lesion failure rate (13.7%). In the whole population,
including complex patients, rates of stent thrombosis were not signiﬁcantly different between patients
with and without diabetes (1.2% vs. 0.8%).
Conclusions The R-ZES is safe and effective in patients with diabetes. Long-term clinical data of
patients with noninsulin-treated diabetes are equivalent to patients without diabetes. Patients with
insulin-treated diabetes remain a higher risk subset. (The Medtronic RESOLUTE Clinical Trial;
NCT00248079; Randomized, Two-arm, Non-inferiority Study Comparing Endeavor-Resolute Stent With
Abbot Xience-V Stent [RESOLUTE-AC]; NCT00617084; The Medtronic RESOLUTE US Clinical Trial (R-US);
NCT00726453; RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent Sys-
tem in a ‘Real-World’ Patient Population [R-Int]; NCT00752128; RESOLUTE Japan–The Clinical Evalua-
tion of the MDT-4107 Drug-Eluting Coronary Stent [RJ]; NCT00927940). (J Am Coll Cardiol Intv
2013;6:357–68) © 2013 by the American College of Cardiology Foundation
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358Patients with diabetes mellitus
are in general at greater risk of
developing cardiovascular
events (1–3), and those under-
going percutaneous coronary
intervention (PCI) for obstruc-
tive coronary artery disease
(CAD) have an increased risk
of restenosis and stent throm-
bosis (4 – 6). Although several
randomized studies (7–10),
registries (11,12), and post hoc
subgroup analyses from large
randomized trials (7,13–15)
have shown drug-eluting stents
(DES) to be superior to bare-
metal stents (BMS) in reduc-
ing neointimal hyperplasia and
therefore restenosis rates in pa-
tients with diabetes, patients
with diabetes continue to be a
higher risk subset associated
with worse clinical outcomes
(16 –18).
The Resolute zotarolimus-
eluting stent (R-ZES) (Medtronic,
Inc., Santa Rosa, California) is a
new-generation DES compris-
ing a thin-strut cobalt alloy
BMS and a durable polymer that
allows prolonged drug elution
for treatment of patients with
complex lesions and clinical
characteristics (19). The safety
and effectiveness of the R-ZES
has been established in over
5,000 patients enrolled in 5 clin-
ical trials, including 2 large in-
ternational trials with minimal
exclusion criteria (20–25). To
obtain a specific indication for use
in patients with diabetes, a pre-
specified analysis plan was devel-
Krozingen, Germany; #Cardiovascular Institute of Buenos Aires, Buenos Aires,
Argentina; **Cardiocenter Kralovske Vinohrady, Charles University, Prague, Czech
Republic; ††Harvard Clinical Research Institute, Boston Massachusetts; ‡‡Soroka
Clinical Research Center, Be’er-Sheva, Israel; §§Stanford University School of
Medicine, Palo Alto, California; Shonan Kamakura General Hospital, Kamakura,
Japan; and the ¶¶Brigham and Women’s Hospital, Harvard Medical School, Boston,
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Medtronic. Dr. Widimsky has received speaker’s honoraria from Medtronic. Dr.
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
CAD  coronary artery
disease
CEC  Clinical Events
Committee
CK  creatinine kinase
DES  drug-eluting stent(s)
EES  everolimus-eluting
stent(s)
FDA  Food and Drug
Administration
ITDM  insulin-treated
diabetes mellitus
LAD  left anterior
descending artery
LCX  left circumflex artery
LMCA  left main coronary
artery
MACE  major adverse
cardiac events
MI  myocardial infarction
NITDM  noninsulin-treated
diabetes mellitus
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
RCA  right coronary artery
R-ZES  Resolute
zotarolimus-eluting stent(s)
SES  sirolimus-eluting
stent(s)
TLF  target lesion failure
TLR  target lesion
revascularization
TVF  target vessel failure
TV-MI  target vessel
myocardial infarction
TVR  target vessel
revascularizationWindecker has received research grant support via institutional grants from Abbott, Moped in collaboration with the U.S. Food and Drug Admin-
istration (FDA) to test the performance of the R-ZES against
a performance goal derived from the published data and pooled
ENDEAVOR (Medtronic, Inc.) data (26). Patients enrolled
in the RESOLUTE Global Clinical Trial Program (Table 1)
served as the study population. This statistical plan was
established before the reporting of the primary outcomes
from the first large randomized all-comers RESOLUTE
trial (RESOLUTE All-comers Trial: A Randomized Com-
parison of a Zotarolimus-Eluting Stent With an
Everolimus-Eluting Stent for Percutaneous Coronary In-
tervention) (21,22). The purpose of this paper is to describe
the process used in obtaining FDA approval for the ex-
panded indication for use in patients with diabetes for the
R-ZES and to report the 2-year clinical outcomes in
complex patients with and without diabetes.
Methods
Patient selection. For this analysis, we pooled patient-level data
for 5,130 patients from 5 controlled studies, with 1 random-
ized (21,22) and 4 single-arm (20,23–25) designs of the
RESOLUTE Global Clinical Trial Program (Table 1). In
concordance with the FDA, the predefined subset of the
pooled cohort was based on the inclusion and exclusion criteria
of studies in patients with diabetes in the published data at the
time the study was designed (Table 2). Because the enrollment
criteria of the randomized RESOLUTE All Comers (21,22) and
the observational RESOLUTE International (24) studies
included more complex patients, the high-risk subsets from
these 2 studies were excluded from the primary analysis.
Patients with acute myocardial infarction (MI) within 72 h of
the index procedure, lesion length27 mm,2 lesions/vessel,
n-stent restenosis, unprotected left main lesions, bifurcation
esions, total occlusions, bypass grafts, thrombus, left ventric-
lar ejection fraction 30%, or serum creatinine 1.6 mg/dl
140 mol/l, according to Table 2) were excluded.
Because the RESOLUTE First-in-Man (20), RESOLUTE
S (23), and RESOLUTE Japan studies (25) used the same
riteria, all patients from these 3 studies were included in the
re-specified analysis.
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edtronic; and has received support from institutional grants from Abbott, Boston
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anofi aventis. All other authors have reported that they have no relationships relevant
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359Thus, our pre-specified analysis population for the
FDA comprised 878 patients with diabetes (Tables 1 to 4).
e also compared these results with the 1,903 patients
ithout diabetes but having the same inclusion/exclusion
riteria. In addition to this pre-specified diabetic cohort,
e evaluated the safety and efficacy of the R-ZES in all
,535 patients with diabetes, including the 657 complex
atients, compared with all 3,595 (also, including com-
lex) patients without diabetes (Table 1).
Diabetic status. Patients were classified as having diabetes if
they were on a regimen of insulin and/or taking oral
antidiabetic agents or on a modified diet to control diabetes.
Patients were considered insulin-treated if they were taking
insulin. Patients were considered noninsulin-treated if they
were taking only oral antidiabetic agents or on a modified
diabetes diet only or both oral agents and a modified diet.
The same criteria were used for all trials in the global
RESOLUTE Clinical Program.
All RESOLUTE trials required the same dual antiplate-
let therapy. A daily dose of at least 75 mg aspirin was
prescribed indefinitely, and 75 mg of clopidogrel was
prescribed daily for at least 6 months.
Study management. Each patient consent form was exter-
ally verified for all studies. Source files were reviewed for all
atients in the RESOLUTE First-In-Man (20), All Com-
rs (21,22), US (23), and Japan (25) studies. For the
ESOLUTE International study, although 25% of patient
harts were externally monitored, there were no differences
n clinical outcomes between fully monitored and partially
onitored patients through 1 year (24). Independent Clinical
vents Committees (CEC) reviewed all serious adverse
vents. All studies were conducted according to the Decla-
ation of Helsinki; all study protocols were approved by local
thics committees.
In addition to the CEC event adjudication process
pecific for each study, a CEC Global Oversight Com-
ittee was organized to ensure consistency in clinical
ata review and to harmonize the interpretation of event
efinitions across the CECs from the 3 largest trials, the
ESOLUTE All Comers, RESOLUTE International,
nd RESOLUTE US trials. The Global Oversight Com-
ittee evaluated the consistency of event adjudication on
he basis of interpretation of event guidelines and pro-
ided recommendations to the respective primary CEC.
he cross-adjudication process included a minimum of
0% of the events from each of the 3 trials (maximum of
00 events/trial) to be cross-adjudicated by an alternate
articipating CEC. The selection of cross-adjudicated
vents was based on event type: death, MI, stent throm-
osis, target lesion, or vessel revascularization.
Choice and deﬁnitions of the clinical outcome parameters. The
rimary objective for the pre-specified FDA analysis popu-
ation was to compare the rate of target vessel failure (TVF),
defined as a composite of cardiac death, target vesselT E P P P A P F
o
 uppe
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360myocardial infarction (TV-MI), and ischemia-driven target
vessel revascularization (TVR) in patients with diabetes at
12 months against a pre-defined performance goal (see the
following text).
Pre-specified secondary objectives included major adverse
cardiac events (MACE), defined as a composite of any
death, any MI, emergent coronary artery bypass, and
ischemia-driven revascularization by any method and target
lesion failure (TLF), defined as a composite of cardiac
death, TV-MI, and ischemia-driven target lesion revascu-
larization (TLR). Any death was considered cardiac unless
a noncardiac cause could be confirmed. Any MI for which
a clear ascription to a target vessel could not be determined
was counted as a TV-MI. All endpoint definitions have
been previously described in detail and are consistent among
the 5 studies (20–25,27). Definite and probable stent
thrombosis was adjudicated according to the Academic
Research Consortium (ARC) criteria (28).
Pre-deﬁned hypothesis and statistical methods. All studies
in the RESOLUTE Global Clinical program were prospec-
tively designed with similar inclusion and exclusion criteria,
clinical documentation forms, endpoint definitions, adjudi-
Table 2. Inclusion and Exclusion Criteria for Patients in the FDA Pre-Speci
Inclusion criteria Clinical inclusion:
Clinical evidence of ischemic heart disease, stabl
Angiographic inclusion: (measurements may be m
Total stent length 100 mm
Target lesion stenosis 50% and 100% with a
Exclusion criteria Clinical exclusion:
Acute myocardial infarction 72 h
Cardiogenic shock or in Killip class IV
History of stroke or transient ischemic attack wit
History of bleeding diathesis or coagulopathy or
Severe hepatic disease
Documented left ventricular ejection fraction 3
Platelet count 100,000 or 700,000 cells/mm3
Serum creatinine level 140 mol/l within 7 day
Procedural exclusion:
PCI of a nontarget vessel within 24 h before the
Planned PCI of any vessel within 30 days post-in
post-procedure
Implantation of a DES in any nontarget vessel w
PCI of a nontarget vessel with a BMS within 30 d
72 h before the index procedure, a post-proc
within 2 SD below ULN required for enrollme
Target lesion requires treatment with a device ot
cutting balloon, atherectomy, laser, or thromb
Any previous or planned treatment of the target
brachytherapy
Angiographic exclusion:
Target lesion located in arterial or venous vessels
Target vessel is excessively tortuous (2 bends 9
Signiﬁcant stenosis (50%) proximal or distal to
5 mm of the origin of the left LAD, LCX, or R
lesion with an obstruction 50%, lesion is at
27 mm; more than 2 lesions/vessel or more
In-stent restenosis
BMS bare-metal stent(s); CK creatine kinase; CK-MB creatine kinase-myocardial band; DES
circumflex; MACEmajor adverse cardiac events; PCI percutaneous coronary intervention; ULNcation procedures, and statistical methodologies. To evalu-ate the performance of the R-ZES in patients with diabetes
against previously published evidence, the following pre-
specified analysis was designed in conjunction with the
FDA to support the approval of an expanded indication for
treatment of patients with diabetes with the R-ZES in the
United States.
All data were analyzed according to the intention-to-treat
principle. To develop the pre-specified performance goal,
we performed a meta-analysis of studies reporting outcomes
of patients with diabetes, treated with sirolimus- (SES) and
paclitaxel-eluting stents (PES) (7,8,13,15,29), and used data
from the ENDEAVOR pooled studies (30) to define an
expected rate of TVF in a diabetic patient population after
treatment with various DES. Thus, the weighted meta-
analytic rate for the 12-month TVF rate was calculated to
be 11.08%. The performance goal was established at 14.5%,
which includes a clinically acceptable margin. The hypothesis for
this analysis accounted for the differences in the protocols of
the individual studies in the published data. Rejection of the
null hypothesis at a 1-sided 0.05 level of significance would
signify that the upper 95% limit around the TVF rate would
be 14.5%. With 80% power, this resulted in a sample size
nalysis Cohort
stable angina, silent ischemia, and/or a positive functional test
y careful visual estimate)
ce diameter 4.0 mm
onths preceding the index procedure
fuse blood transfusions
the most recent evaluation
BC count 3,000 cells/mm3
re index procedure
procedure
ocedure and/or planned PCI of the target vessel(s) within 12 months
days before the index procedure
fore index procedure that results in any MACE. If the BMS is implanted within
serial CK or CK-MB measurement above the ULN of the investigational site,
an standard PCI before stent placement, including, but not limited to,
iration during the index procedure
with other than DES anti-restenotic therapies, including, but not limited, to
each the target lesion)
rget lesion with any of the following characteristics: aorto-ostial location or within
urcation involving a side branch 2.0 mm in diameter; unprotected left main
al to a 45° bend in the vessel; is severely calciﬁed; total lesion length/vessel
3 vessels treated; visible thrombus
eluting stent(s); FDA Food and Drug Administration; LAD left anterior descending; LCX left
r limit of normal; WBCwhite blood cell.fied A
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361goal was developed and agreed in collaboration with the
U.S. FDA and the Harvard Clinical Research Institute
(Boston, Massachusetts).
For baseline comparisons, the 2-sample t test was used for
ontinuous variables, and data are presented as mean SD.
he Fisher exact test was used for binary variables. Time to
vent analyses is reported with the Kaplan-Meier method.
p value of 0.05 was considered statistically significant.
he Harvard Clinical Research Institute, an independent
linical research organization, performed all statistical analyses
ith SAS (version 9.1 or higher; SAS Institute, Inc., Cary,
orth Carolina).
esults
Baseline clinical characteristics for patients in the pre-
specified analysis population by diabetes status are presented
in Table 3. In general, as compared with patients without
diabetes, patients with diabetes were older, more often
female, more often hyperlipidemic or hypertensive, more
often presented with prior PCI or prior coronary artery
bypass surgery but less often were current smokers. Of the
878 patients with diabetes, 250 (28.5%) required insulin
treatment. Baseline characteristics by insulin requirements
Table 3. Baseline Characteristics of the FDA Pre-Specified Analysis Cohort
Baseline Characteristics
R-ZES, Non-DM
(n  1,903)*
R-ZE
(n 
Age (yrs) 63.5 10.8 65.2 10
Male 74.4 (1,415) 66.4 (58
History of smoking 59.3 (1,128) 58.1 (51
Current smoker 22.1 (421) 18.2 (16
Hyperlipidemia 76.0 (1,446) 86.2 (75
History of hypertension 73.1 (1,392) 87.6 (76
Prior myocardial infarction 25.5 (481/1,883) 24.9 (21
History of premature CAD in ﬁrst-degree relative 42.2 (663/1,571) 37.8 (36
Prior percutaneous coronary revascularization 29.5 (562) 34.6 (30
Prior CABG 7.4 (140) 10.5 (92
Reason for revascularization
Stable angina 45.5 (865) 46.2 (40
Unstable angina 31.3 (596) 28.9 (25
Myocardial infarction 6.6 (125) 5.4 (47
Silent ischemia 2.1 (40) 2.1 (18
Vessel location (patient level)
LAD 47.7 (907) 44.8 (39
LCX 30.1 (573) 30.8 (27
RCA 31.1 (591) 34.7 (30
LMCA 0.5 (9) 1.1 (10
Serum creatinine (mol/l) 84.9 19.4 (1,756) 87.1 24
Values are mean  SD, % (n), % (n/N), or mean  SD (N). *All denominators are 1,903 patients and
patients with diabetes and patients without diabetes. ‡All denominators are 628 patients and 250,
with diabetes taking insulin and patients with diabetes not taking insulin.
CABG coronary artery bypass grafting; CAD coronary artery disease; ITDM insulin-treated
abbreviations as in Tables 1 and 2.were more similar between groups; however, there weremore women and more hypertensive patients in the insulin-
treated group (Table 3).
Primary endpoint at 1 year for FDA approval. The 12-month
ate of the primary endpoint of TVF in the 878 R-ZES
atients in the pre-specified diabetic cohort was 7.8% (upper
5% confidence interval: 9.51%) and significantly lower
han the performance goal of 14.5% (p 0.001). Therefore,
he pre-set performance goal for the FDA was met. Addi-
ional safety and efficacy outcomes at 12 months for the
re-specified diabetic cohort were as follows: TLF was
.6%, all death was 2.8%, the combination of cardiac death
nd TV-MI was 3.6%, MACE was 7.5%, and ARC definite
nd probable stent thrombosis was 0.3%.
Clinical outcomes at 2 years. Clinical outcomes at 2 years for
the pre-specified patient population are shown in Tables 4
and 5. The rates of MACE, all death, TVF, and TLF were
significantly higher in the pre-specified diabetic cohort than
in the nondiabetic cohort (Table 4). These outcomes were
also significantly higher in patients with diabetes taking
insulin as compared with the noninsulin-treated cohort
(Table 5). The incidence of ARC definite and probable
stent thrombosis through 2 years was very low, regardless of
the presence or severity of diabetes: in the pre-specified
p Value†
R-ZES NITDM
(n  628)‡
R-ZES ITDM
(n  250)‡ p Value§
0.001 65.5 10.3 64.6 10.0 0.255
0.001 70.4 (442) 56.4 (141) 0.001
0.562 60.2 (378) 52.8 (132) 0.049
0.018 18.6 (117) 17.2 (43) 0.699
0.001 86.0 (540) 86.8 (217) 0.828
0.001 86.0 (540) 91.6 (229) 0.023
) 0.741 25.7 (160/622) 22.9 (56/245) 0.433
) 0.053 37.6 (191/508) 38.4 (78/203) 0.864
0.008 33.9 (213) 36.4 (91) 0.530
0.006 11.1 (70) 8.8 (22) 0.331
0.211 0.105
46.8 (294) 44.8 (112)
28.5 (179) 30.0 (75)
4.3 (27) 8.0 (20)
1.8 (11) 2.8 (7)
0.164 45.4 (285) 43.2 (108) 0.599
0.723 30.9 (194) 30.4 (76) 0.935
0.055 32.8 (206) 39.6 (99) 0.060
0.079 1.3 (8) 0.8 (2) 0.733
) 0.033 86.3 24.2 (586) 89.0 26.7 (230) 0.162
spectively, unless reported otherwise. †p values represent the comparisons at baseline between
ively, unless reported otherwise. §p values represent the comparison at baseline between patients
s mellitus; LMCA left main coronary artery; NITDM noninsulin-treated diabetes mellitus; otherS DM
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362nondiabetic patients and 0.3% in the diabetic group (p 
0.99) (Table 4). Of the 250 patients taking insulin, there
were 2 patients with stent thrombosis, and of the 628
diabetic patients not treated with insulin, only 1 patient had
stent thrombosis throughout the 2 years (Table 5). In the
entire pre-specified diabetic cohort of 878 patients, not a
single patient had a very late stent thrombosis (Tables 4 and 5).
he 30-day, 6-month, and 1- and 2-year rate of dual anti-
latelet therapy usage was 96.1%, 94.8%, 90.3%, and 59.1%,
espectively, for the pre-specified diabetic population.
As in the pre-specified cohort (Tables 4 and 5), in the
hole population, including the complex patients, the rates
f stent thrombosis were not significantly different between
atients with and without diabetes (1.2% vs. 0.8%) as well as
etween insulin-treated and noninsulin-taking patients with
iabetes (1.8% vs. 0.9%) (Table 6). Dual antiplatelet therapy
sage in the overall diabetic and nondiabetic groups at 1
ear was 89.9% and 89.2% and at 2 years was 52.8% and
2.5%, respectively.
Figure 1 shows the cumulative incidence of TLF and its
omponents for patients with diabetes according to insulin
reatment and for patients without diabetes at 1- and 2-year
ollow-up for the pre-specified analysis population. Time-
o-event analyses show that the incidence of TLF (Fig. 1A)
nd its components of cardiac death and TV-MI (Fig. 1B)
nd TLR (Fig. 1C) in patients with noninsulin-treated
iabetes are comparable to that of patients without diabetes.
he clinical events are significantly higher in the insulin-
reated patients than in the noninsulin-treated diabetic and
ondiabetic patients. The analysis of all R-ZES patients,
Table 4. 2-Year Clinical Outcomes for Patients in the Pre-Specified
Analysis Cohort by Diabetes Status
R-ZES, Non-DM
(n  1,903)*
R-ZES DM
(n  878)* p Value
TVF 8.9 (164) 12.1 (104) 0.01
TLF 7.2 (132) 9.5 (82) 0.04
TVR 5.3 (98) 7.9 (68) 0.01
TLR 3.4 (63) 4.8 (41) 0.11
TV-MI 3.1 (58) 2.3 (20) 0.27
Death 2.4 (44) 4.9 (42) 0.001
Cardiac death 1.1 (20) 3.4 (29) 0.001
Noncardiac death 1.3 (24) 1.5 (13) 0.72
Cardiac death or TV-MI 4.1 (76) 5.2 (45) 0.20
Major adverse cardiac events 8.8 (162) 11.3 (97) 0.04
Stent thrombosis (ARC
deﬁnite/probable)
0.4 (8) 0.3 (3) 0.99
Early (30 days) 0.2 (3) 0.2 (2) 0.66
Late (30 and 360 days) 0.2 (3) 0.1 (1) 0.99
Very late (360–720 days) 0.1 (2) 0.0 0.99
Values are % (n). *All denominators at 2-year follow-up are 1,846 and 861 DM and non-DM
cohorts, respectively. For definition of the clinical outcome parameters, please see text.
ARC Academic Research Consortium; other abbreviations as in Table 1.ncluding the nondiabetic and diabetic complex patients,hows the same pattern with significantly higher event rates
n the insulin-treated patients but no difference between the
oninsulin-treated diabetic and the nondiabetic patients
Fig. 2).
iscussion
The present publication describes the effect of the R-ZES
on clinical outcomes in 2 important analyses populations: a
pre-specified cohort of patients from 5 prospectively
planned and harmonized studies (Table 1)—on the basis of
which the FDA approved the specific indication for PCI in
patients with diabetes in the United States; and the full
cohort of patients treated with the R-ZES, including the
more complex patients.
The concept of a pre-speciﬁed prospective cohort analysis
relative to a historical control. In general, randomized trials
re more rigorous than observational studies, yet they are
ften limited in power to address many individual clinical
uestions, due to the sample size of individual populations.
herefore, an acceptable compromise of a prospectively
lanned analysis compared with a performance goal was
erived from historical data. This acceptability of a perfor-
ance goal study on the basis of historical data was used for
.S. approval of the first-generation Taxus Liberté PES
Boston Scientific, Natick, Massachusetts) (31). The
AXUS ATLAS trial (TAXUS ATLAS: A Multi-center,
ingle-arm Study of the TAXUS Liberté-SR Stent for the
reatment of Patients With de Novo Coronary Artery
esions)—a prospective, single-arm study in de novo coro-
Table 5. 2-Year Clinical Outcomes for Patients With Diabetes in the
Pre-Specified Analysis Cohort by Insulin Requirements
R-ZES NITDM
(n  628)*
R-ZES ITDM
(n  250)* p Value
TVF 10.4 (64/617) 16.4 (40/244) 0.02
TLF 7.9 (49) 13.5 (33) 0.01
TVR 7.3 (45) 9.4 (23) 0.33
TLR 4.2 (26) 6.1 (15) 0.29
TV-MI 1.3 (8) 4.9 (12) 0.004
Death 3.9 (24) 7.4 (18) 0.04
Cardiac death 2.8 (17) 4.9 (12) 0.14
Noncardiac death 1.1 (7) 2.5 (6) 0.21
Cardiac death or TV-MI 3.9 (24) 8.6 (21) 0.01
Major adverse cardiac events 9.4 (58) 16.0 (39) 0.008
Stent thrombosis (ARC
deﬁnite/probable)
0.2 (1) 0.8 (2) 0.20
Early (30 days) 0.2 (1) 0.4 (1) 0.49
Late (30 and 360 days) 0.0 0.4 (1) 0.28
Very late (360–720 days) 0.0 0.0 —
Values are% (n/N) or % (n). *All denominators at 2-year follow-up are 617 and 244 for NITDM and
ITDM cohorts, respectively. For definition of the clinical outcome parameters, please see text.Abbreviations as in Tables 1, 3, and 4.
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363nary lesions—compared treatment with the Taxus Liberté
PES versus a matched historical control group of patients
from the TAXUS-IV and -V trials treated with the Taxus
Express PES (31). The Taxus Liberté PES met its perfor-
mance goal as compared with the Taxus Express PES for
the primary clinical endpoint of TVR at 9 months. Subse-
quently, the Promus Element everolimus-eluting stent
(EES) (Boston Scientific) gained U.S. approval by meeting
a performance goal for the primary surrogate endpoint of
late loss at 9 months (32).
For the first time, for the purpose of obtaining this
specific indication with the U.S. FDA, a pre-specified
performance goal was prospectively established to determine
the safety and effectiveness of a DES for patients with
diabetes. Inclusion and exclusion criteria (Table 2) for the
pre-specified analysis cohort were aligned across the 5
RESOLUTE trials to support appropriate comparisons
with patients in the studies used to derive the performance
goal. Therefore, all 5 RESOLUTE trials used consistent
endpoint definitions, and a Global Oversight Committee
cross-adjudicated a subset of events, to ensure consistency in
clinical endpoint review. Patient-level data were then
pooled from the 5,130 patients from the RESOLUTE
Global Clinical Program (Table 1). The rate of TVF in the
pre-specified analysis cohort for the R-ZES–treated pa-
tients with diabetes at 12 months was 7.8%, considerably
less than the predefined DES performance goal of 14.5%
(p 0.001). Thus, the primary endpoint of 1-year TVF met
the performance goal, and the R-ZES achieved the first
FDA approval of the specific expanded indication for PCI
in patients with diabetes. The R-ZES is the only stent in
the United States approved for use in patients with diabetes.
As shown in Figure 1, the 2-year clinical outcomes with
the R-ZES in patients with diabetes not taking insulin
overlap the outcome in patients without diabetes, even
though the patients with diabetes not taking insulin had
significantly more cardiovascular risk factors (Table 3).
The same observation was also made when including the
more-complex patients (Fig. 2). Therefore, the presence
of noninsulin-requiring diabetes does not seem to affect
Table 6. Stent Thrombosis Through 2 Years for All Patients
R-ZES Non-DM
(n  3,595)*
Stent thrombosis (ARC deﬁnite/probable) 0.8 (29)
Early (30 days) 0.5 (18)
Late (30–360 days) 0.2 (7)
Very late (360–720 days) 0.1 (5)
Values are % (n). Stent thrombosis through 2 years for all (including the complex) patients. *All d
denominators at 2-year follow-up are 1,064 and 446 for the NITDMand ITDM cohorts, respectively. P
low-frequency event.
Abbreviations as in Tables 1, 3, and 4.clinical outcomes after treatment with the R-ZES.Superiority of DES versus BMS in patients with diabetes. The
IABETES (Randomized comparison of sirolimus-eluting
tent versus standard stent for percutaneous coronary revas-
ularization in diabetic patients: the diabetes and sirolimus-
luting stent) trial (7) was the first prospective randomized
rial comparing a DES versus BMS in patients with diabetes
s an inclusion criterion (33). In 160 patients, the primary
urrogate endpoint of in-segment late lumen loss at 9
onths was significantly reduced with the Cypher SES
Cordis Corporation, Miami Lakes, Florida) compared with
BMS (0.06  0.4 mm vs. 0.47  0.5 mm). In the
SCORPIUS trial (A German Multicenter, Randomized,
Controlled, Open-Label Study of the Cypher Sirolimus-
Eluting Stent in the Treatment of Diabetic Patients With
De Novo Native Coronary Artery Lesions) (8), the same
primary surrogate endpoint for the same DES was reached
after 8 months in 200 patients with a significant reduction
from 0.75  0.59 mm to 0.17  0.45 mm. In the
DESSERT (An Italian Multicenter, Randomized, Single
Blind Study of the Sirolimus Eluting Stent in the Treat-
ment Of Diabetic Patients With De Novo Coronary Artery
Lesions) study (9), the primary surrogate endpoint of
in-stent late lumen loss was significantly reduced from
0.96  0.61 mm to 0.14  0.33 mm after treatment with
the same DES after 8 months in 150 patients treated with
oral anti diabetic medication and/or insulin.
Drug-eluting stents are preferred over BMS for PCI in
patients with diabetes according to European and U.S.
guidelines (34–36). However, although patients with dia-
betes are an everyday challenge in clinical practice and are
regularly treated with DES, there is no randomized trial of
DES versus BMS with a primary clinical endpoint based on
an adequately calculated sample size for the clinical outcome
in patients with diabetes as an inclusion criterion.
Are there differences between ﬁrst-generation DES in patients
with diabetes? The ISAR-DIABETES trial (Intracoronary
Stenting and Antithrombotic Regimen: Diabetes Mellitus)
(37), was the first randomized study directly comparing 2
DES in patients with diabetes. The primary endpoint was
the surrogate parameter of in-segment late luminal loss after
R-ZES DM
(n  1,535)*
R-ZES NITDM
(n  1,080)†
R-ZES ITDM
(n  455)†
1.2 (18) 0.9 (10) 1.8 (8)
0.8 (12) 0.8 (8) 0.9 (4)
0.3 (4) 0.1 (1) 0.7 (3)
0.1 (2) 0.1 (1) 0.2 (1)
ators at 2-year follow-up are 3,504 and 1,510 for the non-DM and DM cohorts, respectively. †All
are not reported, because the studywas not powered to detect differences between groups for thisenomin
valuesa mean follow-up of 196 days. In 205 patients, the primary
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Figure 1. Cumulative Incidence of TLF and its Components for Patients in Pre-Specified Analysis
Cumulative incidence of target lesion failure (TLF) (A) and its components cardiac death or target vessel myocardial infarction (TVMI) (B) and ischemia-driven
target lesion revascularization (TLR) (C) by diabetic status for patients in the pre-speciﬁed analysis population. DM  diabetes mellitus; ITDM  insulin-treated
diabetes mellitus.
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Figure 2. Cumulative Incidence of TLF and its Components for All Patients
Cumulative incidence of TLF (A) and its components, cardiac death or TVMI (B), and ischemia-driven TLR (C) by diabetic status for all patients from the
RESOLUTE Clinical Trial Program, including the complex patients. Abbreviations as in Figure 1.
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366angiographic endpoint was significantly higher for the
Taxus PES (0.67  0.62 mm) than for the Cypher SES
(0.43  0.45 mm). Although this study was underpowered
for the clinical outcome, the reported TLR rate was 12.0%
in the PES group and 6.4% in the SES group with a wide
confidence interval of 0.82 to 4.27 (p  0.13). The
discussion of the comparison of the 2 first-generation DES
in patients with diabetes has been controversial over the last
years with pros and cons for either PES or SES (38–40).
With the fading use of these 2 first-generation DES,
however, this discussion today is of less practical
importance.
Are newer generation DES better for patients with diabetes?
The ESSENCE-DIABETES trial (Randomized Compari-
son of Everolimus-Eluting Stent Versus Sirolimus-Eluting
Stent Implantation for De Novo Coronary Artery DisEase in
Patients With DIABETES Mellitus) (10) is the first ran-
domized study directly comparing a newer generation DES
(Xience V EES, Abbott Vascular) with a first-generation
DES (Cypher Select and Select Plus SES, Cordis Corpo-
ration) in 300 patients with diabetes. The EES was shown
to be noninferior to the SES for the primary surrogate
endpoint of in-segment late loss at 8 months (0.23  0.27
m vs. 0.37  0.52 mm, pnoninferiority 0.001). Although
nderpowered for clinical outcomes, death, MI, and
schemia-driven TLR were not statistically different be-
ween these 2 DES. A recently published post hoc subgroup
nalysis from 4 pooled randomized trials with 27.6% dia-
etic patients compared the Xience V EES with a first-
eneration DES, Taxus PES (Express and Liberté, Boston
cientific) (41). In these 1,869 patients with diabetes, there
ere no differences in clinical outcomes after 2 years
etween the first- and newer generation DES.
A comparison of our pooled R-ZES 2-year outcomes
ith 2-year outcomes from a recently published pooled EES
nalysis (41) requires caution, because our pre-specified
ohort of patients with diabetes excluded the complex cases
Table 2). By contrast, 3 of the 4 studies in the pooled EES
ata cohort also excluded complex patients with diabetes,
nd only 1 study enrolled complex patients with diabetes
17.2% of all pooled patients). With this caution in mind,
he corresponding 2-year data for the 878 R-ZES (Table 4)
nd the 1,188 EES (41) patients with diabetes are as
ollows: ischemia-driven TLR, 4.8% versus 5.5%; ischemia-
riven TVR, 7.9% versus 8.3%; and definite or probable
tent thrombosis, 0.3% versus 1.6%. Including even the
omplex patients in our analysis, the 2-year rates for definite
r probable stent thrombosis are 1.2% for the 1,335 diabetic
atients treated with the R-ZES (Table 6) versus 1.6% for
he 1,188 patients treated with the EES (41).
The problem of insulin-treated patients. Diabetes, particu-
larly in patients taking insulin, has consistently been shown
to be an independent predictor of adverse outcomes after
stent implantation (42). The results in patients with diabe-tes treated with the R-ZES parallels results of other DES in
that the rates for patients taking insulin have progressively
worse clinical outcomes than the rates for patients not
taking insulin (Figs. 1 and 2). Thus, the overall results in
studies of patients with diabetes strongly depend on the
percentage of patients with diabetes taking insulin (43). The
proportion of patients taking insulin in the studies used to
construct the performance goal ranged from 25.2% to 32.3%
(7,14,30,44–46), consistent with the 28.5% from our anal-
ysis cohort.
In other randomized studies with diabetes as an inclusion
criterion, the proportion of insulin-treated patients was 43%
in the SCORPIUS (8), 25% in the DESSERT (9), and 15%
in the ESSENCE-DIABETES (10) trials. In the post hoc
pooled analysis of the EES and PES (41), 26.4% of patients
taking insulin were included, which is comparable to 28.5%
in our pre-specified cohort. Although these studies were not
used to develop our performance goal, because these data
were only recently published, the clinical results from the
pooled Xience and Taxus studies are consistent with the
rates of the studies used to construct our performance goal.
In accordance with our results for the R-ZES (Figs. 1 and 2),
the EES also showed, as compared with patients with
diabetes not taking insulin, considerably worse 2-year out-
comes for insulin-treated patients with diabetes with signif-
icantly higher ischemia-driven TLR (10.8% vs. 3.7%) and
higher MACE rates (14.8% vs. 8.4%) (41). Although both
of the newer generation DES (i.e., the Resolute ZES and
the Xience V) have improved outcomes compared with
first-generation DES, there is still an opportunity to im-
prove the treatment of CAD in patients taking insulin, and
coronary artery bypass surgery should be strongly conside-
red as an alternative revascularization strategy in these
patients—especially with multivessel disease—as recom-
mended by European and U.S. guidelines (35,36). The
results of the FREEDOM (Future Revascularization Eval-
uation in Patients With Diabetes Mellitus: Optimal Man-
agement of Multivessel Disease) trial, an international
study designed to define the optimal revascularization
strategy for patients with diabetes and multivessel coro-
nary disease, has provided more data with regard to this
unresolved topic (47).
Conclusions
The R-ZES is now indicated for use in the United States
for patients with diabetes and obstructive CAD. Patients
with diabetes not taking insulin had similar clinical out-
comes as patients without diabetes in all patient groups.
Continued attention to improving outcomes for patients
with obstructive CAD and diabetes who are taking insulin
is needed.
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